Cliff Asness's TSHA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 128,764 shares of Taysha Gene Therapies, Inc. (TSHA) worth $876,883, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in TSHA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 82,545 shares. Largest reduction occurred in Q2 2026, reducing 48,545 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Taysha Gene Therapies (TSHA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Taysha Gene Therapies (TSHA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -48,545 | Reduce 27.38% | 128,764 | $6.81 |
| Q1 2026 | +8,447 | Add 5.00% | 177,309 | $4.47 |
| Q4 2025 | +17,862 | Add 11.83% | 168,862 | $5.50 |
| Q3 2025 | +15,234 | Add 11.22% | 151,000 | $3.27 |
| Q2 2025 | +27,867 | Add 25.83% | 135,766 | $2.31 |
| Q1 2025 | +82,545 | Add 325.57% | 107,899 | $1.39 |
| Q4 2024 | -44,117 | Reduce 63.50% | 25,354 | $1.73 |
| Q3 2024 | +69,471 | New Buy | 69,471 | $2.01 |
| Q3 2022 | -10,134 | Sold Out | 0 | $0.00 |
| Q2 2022 | +10,134 | New Buy | 10,134 | $3.75 |
Cliff Asness's Taysha Gene Therapies Investment FAQs
Cliff Asness first purchased Taysha Gene Therapies, Inc. (TSHA) in Q2 2022, acquiring 10,134 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Taysha Gene Therapies, Inc. (TSHA) for 10 quarters since Q2 2022.
Cliff Asness's largest addition to Taysha Gene Therapies, Inc. (TSHA) was in Q1 2025, adding 107,899 shares worth $149,979.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 128,764 shares of Taysha Gene Therapies, Inc. (TSHA), valued at approximately $876,883.
As of the Q2 2026 filing, Taysha Gene Therapies, Inc. (TSHA) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Taysha Gene Therapies, Inc. (TSHA) was 177,309 shares, as reported at the end of Q1 2026.